archive-au.com » AU » C » CSL.COM.AU

Total: 502

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Trial of Novel H1N1 ‘Swine’ Flu candidate vaccine to take place in Adelaide
    be commencing a clinical trial of a candidate vaccine against Novel H1N1 Swine Flu The trial will be undertaken in partnership with Clinical Research Organisation CMAX and the Royal Adelaide Hospital in South Australia Healthy adults aged between 18 and 64 years are being sought to participate and must be available to meet four appointments in Adelaide over a 6 month period The trial will involve participants receiving two injections of the vaccine three weeks apart and will compare a standard with an increased dosage of vaccine Volunteers will need to submit to blood tests to check that they are generating an appropriate immune response to the virus We understand flu vaccines very well from our long experience with yearly seasonal strains as well as research into novel flu vaccines Global Director of Clinical Development at CSL Dr Russell Basser said today We appreciate that new influenza strains like the swine flu can surprise us with properties that mean they might require higher dosing and two injections rather than one to provoke the desired level of immune response in humans CSL will be addressing these questions in the trial to ensure we know the optimum way for the vaccine to

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1244834451885/prdetail.htm (2014-01-05)
    Open archived version from archive


  • CSL and Talecris Agree to Terminate Merger
    to block the transaction As we have previously stated we fundamentally disagree with the FTC case and matters included in their complaint Although we continue to believe in the many customer benefits and significant financial synergies that supported the transaction CSL s Board of Directors did not believe that entering into a protracted litigation process with the FTC with its inherent risks substantial costs and lengthy distraction of CSL management and staff from planning and running our businesses would be in the best interests of our stakeholders Dr McNamee continued While we regret that the transaction cannot be completed CSL remains a well positioned global biopharmaceutical business and will continue to expand on its core strengths We have consistently produced yearon year growth for our shareholders and we are confident in the continued value and growth potential of our stand alone business We continue to have great respect for Talecris and wish them well in the future Lawrence D Stern Talecris Chairman and Chief Executive Officer said After discussions with CSL we have mutually agreed that litigation regarding the antitrust issue was not the path forward Based on a careful analysis of the situation and all alternatives available we believe that termination of the merger agreement is in the best interest of all parties We are disappointed that patients will not benefit from the efficiencies we saw in the proposed combination Talecris continues to focus on its patient community and customers and on building and realizing value for its employees and owners Through the process we developed an even greater appreciation for CSL s competencies professionalism and integrity and we wish Brian and his team well in their future endeavors Both parties will fulfil their obligations for termination contained in the merger agreement As part of the agreement CSL will

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1242703994967/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL announces on-market share buyback
    Australia 09 06 2009 CSL Limited ASX CSL today announced its intention to conduct an on market share buyback of up to 54 863 000 shares 1 This represents approximately 9 of the company s current shares on issue At an assumed price per share of approximately A 29 being CSL s last closing price on Friday 5 June this would represent a total buy back consideration of up to A 1 59 billion Dr McNamee CSL s Managing Director said Last year investors supported CSL with its Talecris acquisition plan by participating in the equity raising Given the company will no longer be acquiring Talecris we think it appropriate for funds to be returned to shareholders The buyback will improve investment return ratios such as earnings per share and return on equity to the benefit of shareholders We are committed to managing the company s capital structure in the interests of our shareholders Given the Company s strong cash flows and balance sheet position CSL is expected to retain a prudent level of gearing following the buyback Shares will be purchased on market during the twelve month period commencing 23 June 2009 2 Download this release CSL announces on

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1242703993084/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL reaffirms its commitment to supply Australia with Novel Influenza A (H1N1) ‘Swine Flu’ Vaccine
    Novel Influenza A H1N1 Swine Flu Vaccine Melbourne Australia 29 05 2009 CSL Biotherapies a subsidiary of CSL Limited Australia s leading biopharmaceutical company welcomes the Rudd Government s recent announcement of its intention to place an order to supply 10 million Australians with a vaccine against Novel Influenza A H1N1 or swine flu CSL is well placed to meet the needs of the Australian population in responding to the

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1242703934562/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Receives USD180 million (approximately AUD230 million) Order from U.S. Government to Produce Novel Influenza A (H1N1) Vaccine
    Influenza A H1N1 Vaccine Melbourne Australia 29 05 2009 CSL Limited ASX CSL Australia s leading biopharmaceutical company announced today that its US subsidiary CSL Biotherapies Inc has signed a contract with the U S Department of Health and Human Services HHS to provide Novel A H1N1 influenza vaccine antigen in bulk form The vaccine will be manufactured at CSL s facility in Parkville Victoria and will support the HHS

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1242703933086/prdetail.htm (2014-01-05)
    Open archived version from archive

  • CSL Limited responds to FTC announcement
    Subscribe to News Alert Search News by Date Contact CSL Home Newsroom News Archive CSL Limited responds to FTC announcement CSL Limited responds to FTC announcement Melbourne Australia 28 05 2009 CSL Limited ASX CSL today was informed that the US Federal Trade Commission FTC will file a complaint in the US Federal District Court to challenge CSL s proposed acquisition of Talecris Biotherapeutics Dr Brian McNamee CEO and Managing Director of CSL Limited said We strongly disagree with the FTC s decision to challenge the deal CSL intends to vigorously oppose the FTC s actions The FTC has failed to recognize that this combination is pro competitive provides significant efficiencies that will improve the supply of biotherapies and is beneficial to the patient community The Commission failed to take into account the substantial remedies that were offered by CSL which addressed their concerns especially in relation to plasma supply Alpha 1 and RhoD Download this release CSL Limited responds to FTC announcement 0 89 MB Analyst Briefing Listen to the recording made during the analyst briefing Media Contacts Australia Dr Rachel David Director Public Affairs CSL Limited Telephone 613 9389 1821 Email rachel david csl com au Tim Duncan

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1242703908232/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    News Archive CSL meets with US Federal Trade Commissioners regarding Talecris Acquisition CSL meets with US Federal Trade Commissioners regarding Talecris Acquisition Melbourne Australia 25 05 2009 CSL Limited today announced that Managing Director Dr Brian McNamee met with U S Federal Trade Commission FTC Commissioners in Washington DC on 22 May to discuss CSL s proposed acquisition of Talecris Biotherapeutics Inc Download this release CSL meets with US Federal

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1242703870345/prdetail.htm (2014-01-05)
    Open archived version from archive

  • News Archive
    Archive Proposed Acquisition of Talecris Biotherapeutics Market Speculation Melbourne Australia 07 05 2009 CSL Limited has become aware of market and media speculation regarding the proposed acquisition of Talecris Biotherapeutics Inc This matter is currently being considered by the U S Federal Trade Commission FTC including the potential for remedies This development is not unusual and provides no indication that the deal will or will not proceed or the timing

    Original URL path: http://www.csl.com.au/s1/cs/auhq/1196562649899/news/1241397150314/prdetail.htm (2014-01-05)
    Open archived version from archive